Mercado de purificación de vectores virales en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2028

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de purificación de vectores virales en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2028

  • Healthcare
  • Published Report
  • May 2021
  • MEA
  • 350 Páginas
  • Número de tablas: 147
  • Número de figuras: 42

Mercado de purificación de vectores virales en Oriente Medio y África, por producto y servicios (productos y servicios), tipo (vectores retrovirales, virus de la vacuna, vectores adenovirales, vectores virales adenoasociados, lentivirus y otros), flujo de trabajo (procesamiento ascendente y descendente), técnica de purificación (ultracentrifugación en gradiente de densidad, ultrafiltración, precipitación, sistemas de extracción de dos fases y cromatografía), escala de operación (preclínica/clínica y comercial), método de administración (in vivo y ex vivo), indicación de enfermedad (cáncer, trastornos genéticos, enfermedades infecciosas , enfermedades veterinarias y otras), aplicación (antisentido y ARNi, terapia génica, terapia celular y vaccinología), usuario final (empresas de biotecnología, empresas farmacéuticas, organizaciones de investigación por contrato, organización de desarrollo y fabricación por contrato (CDMO) e institutos académicos/de investigación), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Egipto y el resto de Oriente Medio y África) Tendencias de la industria y pronóstico para 2028 

Mercado de purificación de vectores virales en Oriente Medio y ÁfricaAnálisis y perspectivas del mercado: mercado de purificación de vectores virales en Oriente Medio y África

Se espera que el mercado de purificación de vectores virales gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 12,4% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 22,17 millones para 2028. La creciente demanda de vectores virales está actuando como un impulsor del mercado de purificación de vectores virales

Los biólogos moleculares utilizan con frecuencia vectores virales para introducir material genético en las células. Este procedimiento puede llevarse a cabo in vivo (dentro de un organismo vivo) o en un cultivo celular (in vitro). Los virus han desarrollado mecanismos moleculares especializados para transportar sus genomas de manera eficiente dentro de las células que infectan. La transducción es la introducción de genes u otro material genético mediante un vector y las células infectadas se denominan transducidas.

La aparición de COVID-19 y la demanda de vacunas virales están impulsando el mercado de purificación de vectores virales. La falta de escalabilidad es una limitación para el mercado de purificación de vectores virales. El creciente número de enfermedades infecciosas actúa como una oportunidad para el mercado de purificación de vectores virales. La escasez de personal calificado es un desafío para el mercado de purificación de vectores virales.

El informe de mercado de purificación de vectores virales proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de purificación de vectores virales, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado de purificación de vectores virales en Oriente Medio y ÁfricaAlcance y tamaño del mercado de purificación de vectores virales

The viral vector purification market is categorized into nine notable segments which are based on the product & services, type, workflow, purification technique, scale of operation, delivery method, disease indication, application and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product & services, the viral vector purification market is segmented into products and services. In 2021, products segment is expected to dominate the viral vector purification market due to availability of diverse range of innovative solutions for vector purification.
  • On the basis of type, the viral vector purification market is segmented into retroviral vectors, vaccine virus, adenoviral vectors, adeno-associated viral vectors, lentivirus and other. In 2021, adeno-associated viral vectors segment is expected to dominate the viral vector purification market due to broad range of infectivity of AAV.
  • On the basis of workflow, the viral vector purification market is segmented into upstream processing and downstream processing. In 2021, upstream processing segment is expected to dominate the viral vector purification market because the viral vectors produced using this process can be harvested from cells in a short window of time post transfection.
  • On the basis of purification technique, the viral vector purification market is segmented into density-gradient ultracentrifugation, ultrafiltration, precipitation, two-phase extraction systems and chromatography. In 2021, chromatography segment is expected to dominate the viral vector purification market because it has been widely used for purification of vaccines and gene therapy vectors.
  • On the basis of scale of operation, the viral vector purification market is segmented into preclinical / clinical and commercial. In 2021, preclinical / clinical segment is expected to dominate the viral vector purification market due to rising investment for research and development activities by major healthcare organizations.
  • On the basis of delivery method, the viral vector purification market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the viral vector purification market due to its high availability and process reliability.
  • On the basis of disease indication, the viral vector purification market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, genetic disorders segment is expected to dominate the viral vector purification market owing to the rising incidence and prevalence of genetic disorders.
  • On the basis of application, the viral vector purification market is segmented into antisense & RNAi, gene therapy, cell therapy and vaccinology. In 2021, gene therapy segment is expected to dominate the viral vector purification market due to broad range of applications in medical sector.
  • On the basis of end user, the viral vector purification market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the viral vector purification market due to increasing initiative activities by various healthcare organizations and government bodies to encourage research endeavour.

Middle East and Africa Viral Vector Purification Market Country Level Analysis

Middle East and Africa viral vector purification market is analysed and market size information is provided by the country, product & services, type, workflow, purification technique, scale of operation, delivery method, disease indication, application and end user as referenced above.

The countries covered in the Middle East and Africa viral vector purification market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and rest of Middle East and Africa.

Middle East and Africa is expected to grow with the fastest CAGR in the forecast period as in the Middle East and Africa’s countries, the demand for viral vector purification is increasing very rapidly due to rapidly increasing population and increasing healthcare expenditure. Saudi Arabia is expected to dominate in Middle East and Africa viral vector purification market as Saudi Arabia is one of the leading countries in the Middle East and Africa utilizing advanced viral vector purification products for treatments.   

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. 

Strategic Initiatives by Manufacturers is Creating New Opportunities for Players in the Viral Vector Purification Market 

El mercado de purificación de vectores virales también le proporciona un análisis detallado del mercado para el crecimiento de cada país. Además, proporciona datos detallados sobre el crecimiento de las ventas de purificación de vectores virales, asociaciones, adquisiciones y acuerdos de distribución entre los actores del mercado de purificación de vectores virales de la región de Medio Oriente y África. Los datos están disponibles para el período histórico de 2011 a 2019. 

Análisis del panorama competitivo y de la cuota de mercado de la purificación de vectores virales

El panorama competitivo del mercado de purificación de vectores virales proporciona detalles por competidor. Los detalles incluidos son la descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de purificación de vectores virales de Oriente Medio y África.

Los principales actores cubiertos en el informe de mercado de purificación de vectores virales de Oriente Medio y África son Applied Biological Materials Inc., Creative Biolabs, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., uniQure NV, BioVision Inc. entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.

Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de purificación de vectores virales. 

Por ejemplo, 

  • En enero de 2021, Thermo Fisher Scientific Inc. anunció que había completado la adquisición del negocio de fabricación de vectores virales de Novsep en Bélgica, lo que ayudará a la empresa a diversificar aún más su mercado.

La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la impresión de la empresa en el mercado de purificación de vectores virales, lo que también brinda el beneficio a la organización de mejorar el crecimiento de sus ventas. 


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW

4.1 DRIVERS

4.1.1 RISING DEMAND FOR VIRAL VECTORS

4.1.2 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION

4.1.3 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT

4.1.4 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY

4.1.5 GROWING USAGE OF AAV VECTORS FOR DELIVERY OF SIRNA IN MAMMALIAN CELLS

4.2 RESTRAINTS

4.2.1 LACK OF SCALABILITY

4.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION

4.3 OPPORTUNITIES

4.3.1 GROWING CANCER BURDEN WORLDWIDE

4.3.2 RISING NUMBER OF INFECTIOUS DISEASES

4.3.3 GROWING GERIATRIC POPULATION

4.3.4 RISING HEALTH CONSCIOUSNESS AND INCREASING SPENDING ON HEALTHCARE

4.4 CHALLENGES

4.4.1 BIOLOGICAL CHALLENGES

4.4.2 SHORTAGE OF SKILLED PERSONNEL

5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: REGULATIONS

1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES

1.1 OVERVIEW

1.2 PRODUCTS

1.2.1 RESIN

1.2.2 KIT

1.2.3 REAGENT

1.2.4 PREPACKED COLUMN

1.2.5 CASSETTE

1.2.6 CAPSULE

1.2.7 FILTER PLATE

1.3 SERVICES

2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE

2.1 OVERVIEW

2.2 CHROMATOGRAPHY

2.2.1 AFFINITY CHROMATOGRAPHY

2.2.2 ION-EXCHANGE CHROMATOGRAPHY

2.2.3 SIZE-EXCLUSION CHROMATOGRAPHY

2.2.4 HYDROPHILIC INTERACTION CHROMATOGRAPHY

2.3 DENSITY-GRADIENT ULTRACENTRIFUGATION

2.4 ULTRAFILTRATION

2.5 PRECIPITATION

2.6 TWO-PHASE EXTRACTION SYSTEMS

3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE

3.1 OVERVIEW

3.2 ADENO-ASSOCIATED VIRAL VECTORS

3.3 ADENOVIRAL VECTORS

3.3.1 MASTADENOVIRUS

3.3.2 AVIADENOVIRUS

3.3.3 SIADENOVIRUS

3.3.4 ATADENOVIRUS

3.3.5 ICHTADENOVIRUS

3.4 LENTIVIRUS

3.5 RETROVIRAL VECTORS

3.5.1 REPLICATION DEFECTIVE

3.5.2 REPLICATION-COMPETENT

3.6 VACCINE VIRUS

3.7 OTHER

4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW

4.1 OVERVIEW

4.2 UPSTREAM PROCESSING

4.3 DOWNSTREAM PROCESSING

5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION

5.1 OVERVIEW

5.2 PRECLINICAL / CLINICAL

5.3 COMMERCIAL

6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE

6.1 OVERVIEW

6.2 IN VIVO

6.3 EX VIVO

7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION

7.1 OVERVIEW

7.2 GENETIC DISORDERS

7.2.1 THALASSEMIA

7.2.2 CYSTIC FIBROSIS

7.2.3 TAY-SACHS DISEASE

7.2.4 SICKLE CELL ANEMIA

7.2.5 OTHERS

7.3 INFECTIOUS DISEASES

7.3.1 MEASLES VIRUS

7.3.2 VESICULAR STOMATITIS VIRUS

7.3.3 NOVEL ADENOVIRUSES

7.3.4 CYTOMEGALOVIRUS

7.3.5 OTHERS

7.4 VETERINARY DISEASE

7.5 CANCER

7.6 OTHER

8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 GENE THERAPY

8.2.1 RECOMBINANT PROTEIN EXPRESSION

8.2.2 FUNCTIONAL ASSAYS

8.2.3 PROTEIN CHARACTERIZATION

8.2.4 IN VITRO TRANSCRIPTION

8.2.5 OTHERS

8.3 CELL THERAPY

8.4 VACCINOLOGY

8.5 ANTISENSE & RNAI

9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER

9.1 OVERVIEW

9.2 ACADEMIC/ RESEARCH INSTITUTES

9.3 PHARMACEUTICAL COMPANIES

9.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)

9.5 BIOTECHNOLOGY COMPANIES

9.6 CONTRACT RESEARCH ORGANIZATIONS

10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY GEOGRAPHY

10.1 MIDDLE EAST & AFRICA

10.1.1 SOUTH AFRICA

10.1.2 SAUDI ARABIA

10.1.3 UAE

10.1.4 EGYPT

10.1.5 ISRAEL

10.1.6 REST OF MIDDLE EAST & AFRICA

11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 COMPANY PROFILE

12.1 THERMO FISHER SCIENTIFC INC.

12.1.1 COMPANY SNAPSHOT

12.1.2 REVENUE ANALYSIS

12.1.3 COMPANY SHARE ANALYSIS

12.1.4 PRODUCT PORTFOLIO

12.1.5 RECENT DEVELOPMENTS

12.2 CYTIVA (A SUBSIDIARY OF DANAHER)

12.2.1 COMPANY SNAPSHOT

12.2.2 REVENUE ANALYSIS

12.2.3 COMPANY SHARE ANALYSIS

12.2.4 PRODUCT PORTFOLIO

12.2.5 RECENT DEVELOPMENT

12.3 MERCK KGAA

12.3.1 COMPANY SNAPSHOT

12.3.2 REVENUE ANALYSIS

12.3.3 COMPANY SHARE ANALYSIS

12.3.4 PRODUCT PORTFOLIO

12.3.5 RECENT DEVELOPMENT

12.4 AGILENT TECHNOLOGIES, INC.

12.4.1 COMPANY SNAPSHOT

12.4.2 REVENUE ANALYSIS

12.4.3 COMPANY SHARE ANALYSIS

12.4.4 PRODUCT PORTFOLIO

12.4.5 RECENT DEVELOPMENT

12.5 FUJIFILM DIOSYNTH BIOTECHNOLOGIES

12.5.1 COMPANY SNAPSHOT

12.5.2 PRODUCT PORTFOLIO

12.6 ADDGENE

12.6.1 COMPANY SNAPSHOT

12.6.2 PRODUCT PORTFOLIO

12.6.3 RECENT DEVELOPMENT

12.7 ALDEVRON

12.7.1 COMPANY SNAPSHOT

12.7.2 PRODUCT PORTFOLIO

12.7.3 RECENT DEVELOPMENTS

12.8 APPLIED BIOLOGICAL MATERIALS INC.

12.8.1 COMPANY SNAPSHOT

12.8.2 PRODUCT PORTFOLIO

12.8.3 RECENT DEVELOPMENT

12.9 BIA SEPARATIONS

12.9.1 COMPANY SNAPSHOT

12.9.2 PRODUCT PORTFOLIO

12.9.3 RECENT DEVELOPMENTS

12.1 BIO-RAD LABORATORIES, INC.

12.10.1 COMPANY SNAPSHOT

12.10.2 REVENUE ANALYSIS

12.10.3 PRODUCT PORTFOLIO

12.10.4 RECENT DEVELOPMENT

12.11 BIOVISION INC.

12.11.1 COMPANY SNAPSHOT

12.11.2 PRODUCT PORTFOLIO

12.11.3 RECENT DEVELOPMENT

12.12 BATAVIA BIOSCIENCES B.V.

12.12.1 COMPANY SNAPSHOT

12.12.2 PRODUCT PORTFOLIO

12.12.3 RECENT DEVELOPMENT

12.13 CREATIVE BIOGENE

12.13.1 COMPANY SNAPSHOT

12.13.2 PRODUCT PORTFOLIO

12.13.3 RECENT DEVELOPMENTS

12.14 CREATIVE BIOLABS

12.14.1 COMPANY SNAPSHOT

12.14.2 SERVICE PORTFOLIO

12.15 IDT BIOLOGIKA GMBH

12.15.1 COMPANY SNAPSHOT

12.15.2 PRODUCT PORTFOLIO

12.15.3 RECENT DEVELOPMENTS

12.16 PROBIOGEN AG

12.16.1 COMPANY SNAPSHOT

12.16.2 PRODUCT PORTFOLIO

12.16.3 RECENT DEVELOPMENTS

12.17 SIRION-BIOTECH GMBH

12.17.1 COMPANY SNAPSHOT

12.17.2 PRODUCT PORTFOLIO

12.17.3 RECENT DEVELOPMENTS

12.18 TAKARA BIO INC.

12.18.1 COMPANY SNAPSHOT

12.18.2 REVENUE ANALYSIS

12.18.3 PRODUCT PORTFOLIO

12.18.4 RECENT DEVELOPMENTS

12.19 UNIQURE N.V.

12.19.1 COMPANY SNAPSHOT

12.19.2 REVENUE ANALYSIS

12.19.3 PRODUCT PORTFOLIO

12.19.4 RECENT DEVELOPMENT

12.2 WAISMAN BIOMANUFACTURING

12.20.1 COMPANY SNAPSHOT

12.20.2 PRODUCT PORTFOLIO

12.20.3 RECENT DEVELOPMENTS

13 QUESTIONNAIRE

14 RELATED REPORTS

Lista de Tablas

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SERVICES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA DENSITY-GRADIENT ULTRACENTRIFUGATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA ULTRAFILTRATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA PRECIPITATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA TWO-PHASE EXTRACTION SYSTEMS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA ADENO-ASSOCIATED VIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA LENTIVIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA VACCINE VIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA PRECLINICAL / CLINICAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA COMMERCIAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA IN VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA EX VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA VETERINARY DISEASE IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA CANCER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA CELL THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA VACCINOLOGY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA ANTISENSE & RNAI IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 76 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 77 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 78 SOUTH AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 79 SOUTH AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 80 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 81 SOUTH AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 82 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 96 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 UAE VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 100 UAE PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 101 UAE VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 102 UAE CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 103 UAE VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 UAE RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 UAE ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 UAE VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 107 UAE VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 108 UAE VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 109 UAE VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 110 UAE GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 111 UAE INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 112 UAE VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 113 UAE GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 114 UAE VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 115 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 116 EGYPT PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 117 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 118 EGYPT CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 EGYPT RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 EGYPT ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 123 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 124 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 125 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 126 EGYPT GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 127 EGYPT INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 128 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 129 EGYPT GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 130 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 131 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 132 ISRAEL PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 133 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 134 ISRAEL CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 135 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 136 ISRAEL RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 ISRAEL ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 139 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 140 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 141 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 142 ISRAEL GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 143 ISRAEL INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 144 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 145 ISRAEL GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 146 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 147 REST OF MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

 

Lista de figuras

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION

FIGURE 12 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION IS DRIVING THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET

FIGURE 15 ESTIMATED NUMBER OF NEW CASES IN MALE AND FEMALE (ALL AGE GROUP) WORLDWIDE IN 2018

FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2020

FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2021-2028 (USD MILLION)

FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, CAGR (2021-2028)

FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2020

FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2021-2028 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, CAGR (2021-2028)

FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, LIFELINE CURVE

FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2020

FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 13 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2020

FIGURE 14 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2021-2028 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, CAGR (2021-2028)

FIGURE 16 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, LIFELINE CURVE

FIGURE 17 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2020

FIGURE 18 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2021-2028 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, CAGR (2021-2028)

FIGURE 20 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2020

FIGURE 22 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2021-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2020

FIGURE 26 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2021-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2020

FIGURE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2020

FIGURE 34 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 35 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: SNAPSHOT (2020)

FIGURE 38 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020)

FIGURE 39 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 40 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE (2021-2028)

FIGURE 42 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY SHARE 2020 (%)

 

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Middle East and Africa Viral Vector Purification Market is projected to grow at a CAGR of 12.4% during the forecast period by 2028.
The future market value of the Middle East and Africa Viral Vector Purification Market is expected to reach USD 22.17 million by 2028.
The major players in the Middle East and Africa Viral Vector Purification Market are Applied Biological Materials Inc., Creative Biolabs, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., uniQure N.V., etc.
The countries covered in the Middle East and Africa Viral Vector Purification Market are Saudi Arabia, South Africa, UAE, Israel, Egypt and rest of Middle East and Africa.
On the basis of application, the Middle East and Africa Viral Vector Purification Market is segmented into antisense & RNAi, gene therapy, cell therapy and vaccinology.